Skip to content

effect of Tukhm-e-Hulba and Gilo in Type 2 Diabetes Mellitus

A Comparative Clinical Study of Tukhm-e-Hulba and Gilo in Dayabitus Shakri (Type 2 Diabetes Mellitus) with Control drug in its Management - NILL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/066275
Enrollment
60
Registered
2024-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Tablet (600mg) made of aqeous extract of Tukhme Hulba and Gilo: In the Test group, tablets made of aqeous extract of Tukhme Hulba and Gilo will be given in the dose of 1 tab (600 mg eac

Sponsors

Dept Moalejat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any one of these: Fasting blood sugar (FBS): 126mg/dl to 180mg/dl (or) Post Prandial blood sugar (PPBS): 200mg/dl to 250mg/dl (or) Glycated haemoglobin (HbA1C): 6.0% to 7.5% Patient willing to sign the written informed consent. Newly diagnosed patient of Type 2 Diabetes mellitus. Known case of Diabetes mellitus not taking any traditional or conventional treatment. Urine for microalbuminuria: A1 and A2 Patient having BMI more than or equal to 18.5

Exclusion criteria

Exclusion criteria: Patients below 30 years and above 60 years of age. Presence of any evidence suggestive of microvascular and macrovascular complications. Patients of Malnutrition related Diabetes mellitus (MRDM). Any co-morbid condition. Pregnant and lactating women. Patient who fail to give consent. Patient who fail to follow up. Mentally retarded person. Patient having uncontrolled hypertension.

Design outcomes

Primary

MeasureTime frame
Improvement in: Blood sugar fasting Blood sugar PP No improvement less than 10 mg/dl Mild improvement 10-20 mg/dl Moderate improvement 20-30 mg/dl Significant improvement more than 30 mg/dl Improvement in HbA1C levels No improvement less than 0.2 mg/dl Mild improvement 0.2-0.4 mg/dl Moderate improvement 0.4-0.6 mg/dl Significant improvement more than 0.6 mg/dlTimepoint: Blood sugar fasting: Baseline, 15th, 30th, 60th, 90th day Blood sugar PP : Baseline, 15th, 30th, 60th, 90th day HbA1C levels : Baseline, 90th day

Secondary

MeasureTime frame
Improvement in Urine for microalbuminuria A1 Normal to mildly increased less than 30 A2 Moderately increased 30 -300 A3 Severely increased More than 300 Improvement in subjective parameters (Polyuria, Polydipsia, Polyphagia, Nocturia, Increased fatigue) Reduction in BMI to normal range Reduction of waist circumference to normal rangeTimepoint: Subjective parameters: 0th, 15th , 30th , 45th , 60th , 90th day Urine (routine & microscopic) :at beginning and end of study Urine for microalbuminuria :at beginning and end of study BMI :at beginning and end of study Waist circumference :at beginning and end of study

Countries

India

Contacts

Public ContactMohd Mushfiq

Aligarh Muslim University

tabassum94tariq@gmail.com8218114385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026